Molybdenum Side Effects

Reported Molybdenum side effects

Molybdenum at dietary intake levels (45-150 μg/day) is extremely well tolerated. The RDA (45 μg) is easily met and the UL (2,000 μg) provides a wide safety margin. Acute and chronic toxicity at nutritional doses is essentially non-existent. Concerns center on supratherapeutic doses (≥10 mg/day), occupational exposure to molybdenum dust, and the specific effects of TTM in therapeutic copper chelation. Gastrointestinal. Standalone molybdenum supplements at typical doses (150-500 μg/day) are well tolerated. Higher doses (1-2 mg) may produce mild dyspepsia or loose stools in some users. Hyperuricemia and gout. Very high molybdenum intake (10+ mg/day) increases xanthine oxidase activity and uric acid production, potentially precipitating gout in susceptible individuals. Armenian cases of dietary molybdenosis (associated with very high soil molybdenum in certain agricultural regions) included gout-like symptoms at intakes estimated at 10-15 mg/day. This is not a concern at typical supplement doses. Copper deficiency. Chronic high-dose molybdenum with low-copper diets could precipitate copper deficiency via thiomolybdate complex formation (the basis of TTM therapy applied inadvertently). This is exploited therapeutically (TTM in Wilson disease) but is a concern at chronic intake above 1-2 mg/day molybdenum with low dietary copper. Animal molybdenosis in ruminants is the classic agricultural example. Tetrathiomolybdate-specific concerns (therapeutic use): Copper deficiency: aplastic anemia, neutropenia, myelopathy (dorsal column demyelination similar to vitamin B12 deficiency). TTM therapy requires copper monitoring and dose adjustment. Hepatic: rare hepatotoxicity in TTM trials. Bone marrow suppression: related to copper deficiency; reversible with dose reduction. Neurologic worsening: less than penicillamine but can occur early in therapy. Gastrointestinal irritation. Molybdate salts at gram-level doses (not typical consumer use) may cause gastritis. Pulmonary. Occupational inhalation of molybdenum dust (molybdenum mining, MoO3 production, tungsten alloy manufacture) has been associated with pneumoconiosis and mild pulmonary dysfunction in some worker cohorts. No carcinogenicity at typical exposure levels. Reproductive. Animal studies at very high molybdenum doses have reported fetal developmental abnormalities; human reproductive studies are limited. Pregnancy supplementation should stay within RDA/UL (50 μg/day RDA, 2,000 μg/day UL). Renal. Molybdenum is primarily renally excreted. In severe renal insufficiency, molybdenum handling may be altered, though clinical significance is modest. High doses should be avoided in advanced kidney disease. Hepatic. Molybdenum does not significantly accumulate in liver except in TTM Mo-S-Cu complex context. No specific hepatic concerns at dietary doses. Drug interactions: Allopurinol and febuxostat: both inhibit xanthine oxidase, so concurrent high-dose molybdenum may be antagonistic at the enzyme level; clinically insignificant at typical supplement doses. Copper supplements: high-dose molybdenum may reduce copper absorption via thiomolybdate formation; separate supplementation or reduce molybdenum if both needed. Sulfur-containing drugs (acetylcysteine, methionine, cysteine): sulfur compounds may reduce molybdenum absorption via competition at transporters. Sulfate and high-sulfate diets: reduce molybdenum absorption. Pregnancy. AI 50 μg/day. Standard multivitamin content (45-75 μg) is appropriate. High-dose supplementation not recommended in pregnancy. Lactation. AI 50 μg/day. Standard multivitamin content appropriate. Children. RDA ranges 17-43 μg/day (age-dependent). Pediatric multivitamins contain appropriate molybdenum. Standalone pediatric molybdenum is not indicated outside of specific medical conditions (MoCD, parenteral nutrition). Drug metabolism via aldehyde oxidase. AOX1 metabolizes several drugs; theoretical interactions with molybdenum status are not clinically significant at physiologic molybdenum ranges. Occupational exposure. Molybdenum workers should follow OSHA standards (PEL 15 mg/m3 for soluble molybdenum, 15 mg/m3 total molybdenum dust). Inhalation of molybdenum dust in mining, refining, metallurgy, and tungsten-carbide tool manufacturing requires PPE and surveillance. Hypersensitivity. Molybdenum contact dermatitis is rare; a few case reports of hypersensitivity to dental alloys containing molybdenum have been described. Long-term safety. Human data on molybdenum supplementation at supratherapeutic doses (1-5 mg/day) for years is limited. Multivitamin-level dosing (45-150 μg/day) has extensive ambient safety data.

When to continue, reduce, or stop Molybdenum

Molybdenum contraindications

Absolute contraindications: Known hypersensitivity to molybdenum (extremely rare). TTM specifically in copper-deficient patients without close monitoring. Fosdenopterin: reserved for MoCD type A specifically; not effective in MoCD B or C. Relative contraindications / use with medical supervision: Advanced chronic kidney disease (eGFR <30): limit to RDA-level dosing given renal excretion. Active gout: avoid supratherapeutic doses (>1 mg/day) which might modestly increase uric acid. Pregnancy beyond first trimester at supra-AI doses. Active Wilson disease: under hepatology care with specific TTM protocols; self-supplementation contraindicated. Populations requiring caution: Known xanthinuria or xanthine stone formers. Chronic copper supplementation users at very high molybdenum doses (potential copper deficiency at 5+ mg/day Mo). Sulfite-sensitive individuals who are expecting benefit that may not materialize from molybdenum supplementation. Clinical warning signs — reassess molybdenum supplementation: Unexplained gout attack or hyperuricemia. Copper deficiency signs (anemia, neutropenia, neurologic symptoms) in context of chronic high-dose molybdenum. Unexplained fatigue or GI symptoms with high-dose use. Drug interactions: Copper supplements: high-dose interaction (thiomolybdate formation); separate or avoid combination. Sulfate-containing drugs and high-sulfate diets: reduce molybdenum absorption. Allopurinol, febuxostat: no clinically significant interaction at typical supplement doses. Drugs metabolized by aldehyde oxidase (methotrexate, zaleplon, ziprasidone, famciclovir): theoretical interactions at physiologic status unlikely clinically significant. NSAIDs: no known interaction. TTM-specific contraindications (therapeutic use): Active copper deficiency (baseline). Severe bone marrow suppression. Pregnancy (fetal copper requirements; use alternative Wilson therapy if needed). Known hypersensitivity. Close monitoring required for serum copper, ceruloplasmin, CBC, LFTs. Fosdenopterin contraindications (therapeutic use): MoCD types B or C (no benefit; drug does not bypass the block). Should be initiated as early as possible (ideally pre-symptomatic or very early symptomatic) for maximum benefit. Lactation: RDA 50 μg/day. Standard multivitamin content appropriate. Avoid high-dose supplementation. Driving and operating machinery: no specific concerns; molybdenum has no sedating or impairing effects. Regulatory status: Dietary supplement category in US (DSHEA 1994). No specific FDA-approved disease indications for consumer molybdenum. Fosdenopterin approved for MoCD type A (2021). TTM not FDA-approved (used under specialty protocols for Wilson disease). ALXN1840 FDA approval declined 2022; development ongoing. Laboratory interferences: none of clinical significance. Environmental exposure: drinking water molybdenum is generally not a health concern; occupational exposure is managed under OSHA standards.

Why vendor quality drives Molybdenum side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Molybdenum side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .